Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Harrow Health Inc(HROW)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HROW
09/25/2026: HROW (1-star) is currently NOT-A-BUY. Pass it for now.
Harrow Health is a commercial-stage specialty pharmaceutical company focused on the ophthalmic market. Its primary strength lies in a targeted sales strategy that connects directly with eye surgeons to provide branded medicine. The company's growth story centers on an aggressive acquisition-led strategy, securing established drug portfolios to scale its commercial presence. However, investors must consider risks associated with high debt levels, product concentration, and intense competition from larger industry players. As a non-dividend paying growth stock, Harrow is better suited for investors comfortable with the volatility inherent in small-cap healthcare companies. Development of core assets like IHEEZO and successful debt management remain key factors to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company pursues aggressive, acquisition-driven growth to scale its footprint in the ophthalmic sector. |
| Momentum investor | Mixed fit | Momentum fits only during periods of strong price appreciation and successful integration of major acquisitions. |
| Value investor | Weak fit | The company's reliance on debt and acquisition-led growth makes traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | Harrow reinvests all capital into growth and acquisitions, offering no dividend yield. |
| Low-risk investor | Weak fit | High volatility and the risks associated with pharmaceutical commercialization make this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant fluctuations due to small-cap status and acquisition-driven business cycles. |
| Valuation risk | Medium / high | Investors pay for future growth that must be realized through successful product integration and sales scaling. |
| Competition risk (Ophthalmic Pharma) | High | Large incumbents like Alcon possess massive resources that can challenge Harrow's market share. |
| Business quality | Medium | While the product portfolio is growing, the company remains highly leveraged and dependent on external acquisitions. |
| Dividend income | Low / none | There is no dividend income for investors seeking steady payouts. |
| Execution risk | High | Successful growth depends entirely on the ability to integrate and market newly acquired drug assets effectively. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 1.44% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio - | 1Y Target Price 65 |
Price to earnings Ratio - | 1Y Target Price 65 | ||
Volume (30-day avg) 535.9K shares | Beta 0.24 | 52 Weeks Range 28.54 - 54.85 | Updated Date 09/24/2026 |
52 Weeks Range 28.54 - 54.85 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Branded Pharmaceuticals | Revenue from sales of FDA-approved ophthalmic drugs like IHEEZO and acquired Novartis assets. | The company makes money by selling essential medicines to eye surgeons and their patients. |
| Compounding Services | Legacy revenue from custom-compounded medications. | Smaller portion of revenue from specialized, non-standard pharmaceutical preparations. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 46.73 | Enterprise Value 1.48B | Price to Sales(TTM) 4.5 |
Enterprise Value 1.48B | Price to Sales(TTM) 4.5 | ||
Enterprise Value to Revenue 5.36 | Enterprise Value to EBITDA 129.82 | Shares Outstanding 37.49M | Shares Floating 28.93M |
Shares Outstanding 37.49M | Shares Floating 28.93M | ||
Percent Insiders 15.38 | Percent Institutions 58.56 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Harrow Health Inc
Exchange NASDAQ | Headquarters Nashville, TN, United States | ||
IPO Launch date 2007-09-28 | CEO, Chairman of the Board & Founder Mr. Mark L. Baum J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 373 | Website https://www.harrow.com |
Full time employees 373 | Website https://www.harrow.com | ||
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.